Abstract 785P
Background
GTN involves malignant entities, such as choriocarcinoma (GCC), epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT), all of which can metastasize and be fatal if not treated in a timely and effective manner. We aimed to develop machine-learning (ML)-based prognostic models for patients with GTN to improve treatment decisions and personalized medicine.
Methods
The SEER database provided the data used for this study’s analysis (2000–2019). Patients were excluded if they did not meet certain criteria, such as a histology-confirmed diagnosis, previous history of cancer or other concurrent malignancies, non-placental origins, or unknown data. Cox regression and ML algorithms were used to construct prognostic models for predicting the 5-year survival. Patient records were randomly divided into a training set (70%) and a validation set (30%). A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of ML models.
Results
This study included 725 patients, of whom 139 had ETT, 107 had PSTT, and 479 had GCC. The median age was 37 years, and the most common stage was distant metastasis (n=330). The average tumor size was 6.13 cm, and 75.9% of patients underwent chemotherapy, 57.9% underwent surgery, and 4.3% underwent radiotherapy. Multivariate Cox regression revealed that older age, marital status, metastasis, and radiotherapy were poor prognostic factors, whereas surgery was a good prognostic factor. ML models revealed that the most important factors that influenced the model prediction performance were tumor size, years of diagnosis, and race. The online calculator, which is based on ML models, allows for real-time personalized survival predictions, and can be accessed through the following link: https://sakhrshwayyat.shinyapps.io/Gestational_Trophoblastic_Neoplasia/.
Conclusions
Our study revealed the critical components of clinical decision-making. The designed models and online prediction resources can significantly facilitate personalized treatment planning and enhance the clinical outcomes of patients with GTN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
880P - Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial
Presenter: Thorsten Fuereder
Session: Poster session 02
881P - Cetuximab with dalpicilib in patients with HPV-negative, anti-PD-1 resistant R/M HNSCC
Presenter: Ju Houyu
Session: Poster session 02
882P - Quitting smoking after diagnosis of head and neck cancer is associated with reduced risk of mortality: A multicentric prospective cohort study
Presenter: Mahdi Sheikh
Session: Poster session 02
883P - Oral rehabilitation after mandibular reconstruction for head and neck malignancy: A multicenter study
Presenter: lise marie Roussel
Session: Poster session 02
884P - Real-world treatment patterns and survival outcomes associated with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A German claims data analysis
Presenter: Thomas Kuhnt
Session: Poster session 02
885P - Different patterns of treatment failure between p16+ and p16- patients affected by oropharyngeal carcinoma (OPC) undergoing (chemo)radiation
Presenter: Riccardo Gili
Session: Poster session 02
887P - Treatment of elderly patients with locally advanced laryngeal carcinoma with dose-intense chemotherapy followed by radio-chemotherapy: Evading surgical intervention
Presenter: Maher Salamoon
Session: Poster session 02
888P - Comparing paclitaxel plus cisplatin versus cisplatin in concurrent chemoradiotherapy for stage IV locoregionally advanced nasopharyngeal carcinoma: A phase II randomized trial
Presenter: Ling Guo
Session: Poster session 02